Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04552288
Other study ID # 20-344
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 16, 2020
Est. completion date March 16, 2025

Study information

Verified date November 2023
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date March 16, 2025
Est. primary completion date March 16, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Patients must have pathologically or cytologically confirmed solid or hematologic cancers. OR - Patient is receiving alpelisib for PIK3CA-Related Overgrowth Spectrum disorder. - Female and male aged 18 to 85 years, inclusively, at the time of Week 0/Day 1 of treatment. - Patients must have a therapy-related CTCAE grade 2/3 (See Appendix A)cutaneous adverse event defined as any cutaneous reaction listed below and blood eosinophil counts of at least .3 K/mcl. - Rash maculo-papular - Bullous dermatitis - Pruritus - Urticaria - Eczema - Patients must plan to continue on culprit drugs (cancer patients). - Patients planning to receive alpelisib indicated for PIK3CA-Related Overgrowth Spectrum disorder OR patients receiving immunotherapy and/or targeted therapy, including but not limited to the following agents, will be eligible for inclusion: - Immunotherapies: ipilimumab, nivolumab, pembrolizumab, avelumab, durvalumab, atezolizumab tremelimumab. - Targeted therapies: trastuzumab, pertuzumab, alpelisib, osimertinib, everolimus, temsirolimus, sorafenib, regorafenib. - Patients using topicals/orals for indication of skin rash/pruritus for at least 7 days should continue using these drugs for the study duration - Adequate bone marrow, liver and renal function: - Total bilirubin = 1.5 x the upper limit of normal (ULN) - Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) = 2.5 x ULN (= 5 x ULN for subjects with liver involvement of their cancer) - Serum creatinine = 1.8 xULN or calculated creatinine clearance >45 ml/min - Platelet count > 50 K/mcL , hemoglobin (Hb) > 8 g/dL, absolute neutrophil count (ANC) >1.0 K/mcL. Blood transfusion to meet the inclusion criteria will not be allowed. - ECOG performance status 0-1 (see Appendix C). - Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure. - Female patients are authorized to participate if they meet the following criteria: - Women of child bearing potential must meet both of the following conditions: - Have a negative serum pregnancy test prior to enrollment and within 14 days prior to administration of the investigational product (IP). - Patient must use an effective form of birth control (confirmed by the Investigator) throughout the study duration and within 16 weeks after last dose of IP. - Female subjects who cannot bear children as evidenced by one or more of the following: - Bilateral Oophorectomy - Bilateral Salpingectomy - Bilateral Salpingectomy-Oophorectomy - Hysterectomy - Menopause (no menses = 1 year prior to treatment) - Surgical Sterilization (i.e., tubal ligation or blockage) Note: If criteria not met, patient should be regarded as having child bearing potential - Subject must be able to receive a subcutaneous injection. - New/worsening ercAE within 90 days prior to study enrollment. Note: This assessment will be performed by the treating investigator. Exclusion Criteria: - Concurrent use of another investigational drug or device for the ercAE (i.e., outside of study treatment) during, or within 4 weeks of treatment. - Patients receiving prednisone = 20mg a day. - Known use of anti-IL-5 agents or biologics for the treatment of asthma which are known to decrease blood eosinophil levels. - Patients cannot use new topicals or medications for indication of pruritus or skin rash - Known history of anaphylaxis to biologic therapy. - A helminthic parasitic infection diagnosed within 24 weeks prior to the first treatment, that had not been treated with, or has failed to respond to, standard of care therapy. - Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy. - Active infection that would impair the ability of the patient to receive study treatment. - Women who are pregnant or breast-feeding. - Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation. - Receipt of live attenuated vaccines 30 days prior to the date of randomization ° Receipt of inactive/killed vaccinations (e.g., inactive influenza) is allowed provided they were not administered within 1 week before/after any investigational product administration. - Known history of allergy or reaction to the investigational product formulation

Study Design


Intervention

Drug:
Benralizumab
All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.

Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center Basking Ridge New Jersey
United States Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) Commack New York
United States Memorial Sloan Kettering Westchester Harrison New York
United States Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (Limited Protocol Activities) Hauppauge New York
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events To evaluate the percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events to grade =1 resulting from checkpoint inhibitors (CPIs) or targeted therapies with absolute blood eosinophil counts of at least .3 K/mcl. 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2